Rock inhibitors target SRSF2 leukemia by disrupting cell mitosis and nuclear morphology
M. Su, T. Fleisher, I. Grosheva, M. B. Horev, M. Olszewska, B. Haim, A. Plotnikov, S. Carvalho, Y. Moskovitz, M. Minden, N. Chapal-Ilani, E. P. Papapetrou, N. Dezorella, T. Cheng, N. Kaushansky, , L. I. Shlush
This study identifies ROCK inhibitors as effective targeting agents for SRSF2 mutant leukemia by disrupting mitosis and nuclear morphology in vitro and in xenograft models.
bioRxiv · Feb 15, 2022 · PreprintCancer Biology